Navigation Links
Some patients with treatment-resistant colorectal cancers may have a new option
Date:6/2/2013

PHILADELPHIA A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET inhibitor drugs.

The MET gene is known to be amplified in about 10 percent of colorectal cancers, and is associated with worse prognosis.

The paper was also presented as part of an oral session at the 2013 American Society of Clinical Oncology Annual Meeting.

"Our studies provide evidence that colorectal cancer resistance to anti-EGFR therapies can be driven by MET gene amplification," said Alberto Bardelli, Ph.D., associate professor in the Department of Oncology at the University of Torino in Italy. "But what is more exciting is that we were able to detect these amplifications in the blood."

A subset of metastatic colorectal cancers responds to the anti-EGFR drugs cetuximab and panitumumab, but almost always develops resistance within several months of the initiation of therapy, according to Bardelli. Mutations in genes related to EGFR signaling, including KRAS, BRAF and NRAS, account for about 60 percent of the cases that develop resistance; the cause of resistance in tumors without these mutations is unknown.

"Unfortunately, patients whose tumors recur after anti-EGFR therapy are out of further options currently," said Bardelli. "The possibility that we can identify those who have MET amplification using a blood test is exciting because they might be treated with MET inhibitors."

Bardelli and his colleagues analyzed tumors from seven patients who developed resistance subsequent to anti-EGFR therapy, and identified three who did not have the previously known mutations. Using next-generation sequencing, they demonstrated amplification of the MET gene in these three tumor samples.

Blood samples collected at regular intervals during treatment with anti-EGFR therapy until relapse were available for two of the three patients. The researchers were able to detect MET amplification in the blood, and they demonstrated it occurred prior to relapse. The ability to detect MET amplification in blood provides a noninvasive, highly sensitive method for monitoring and predicting drug resistance and tumor recurrence, according to Bardelli.

Using "xenopatients" patient-derived, drug-resistant colorectal cancers grafted and grown in mice the researchers identified a novel, biologically distinct subset of tumors that were resistant to anti-EGFR drugs and did not have alterations in KRAS, BRAF or NRAS but carried MET amplification. The researchers further confirmed the overexpression of the MET gene and MET protein in these tumors using special techniques called fluorescent in situ hybridization and immunohistochemistry.

As a next step, the researchers tested the efficacy of the clinically approved MET inhibitor crizotinib in two xenopatients. According to Bardelli, a MET inhibitor in combination with an anti-EGFR drug caused maximum antitumor activity and sustained response in both xenopatients. He added that this provided proof of concept that MET inhibitors, alone or in combination with anti-EGFR therapies, offer novel therapeutic opportunities.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Therapy that heats and destroys bone tumors eases patients pain
2. Test helps target glioblastoma patients most likely to benefit from bevacizumab
3. Study finds glioblastoma patients treated with bevacizumab experience reduced cognitive function and quality of life
4. Atlanta Hearing Institute Helps Atlanta Hearing Loss Patients Both Young and Old Dramatically Improve Quality of Life
5. Dr. Richard Shuldiner, First in California to Utilize New E-Scoop Glasses, Improve Way of Life for Low Vision Patients Suffering with Macular dDegeneration (ARMD)
6. Poorer Patients Often Less Happy With Knee Replacement
7. Obese Patients May Be More Prone to Doctor Shopping
8. Foundation Recognizes Patient Navigator Jackie Glenn of The Cancer Center at Lake Manassas for Work with Breast Cancer Patients
9. Researchers narrow the search for biomarkers of drug resistance in head and neck cancer patients
10. The Lap Band Center Announces Ways for Patients to Find Out How to Lose Weight Quickly and Efficiently
11. Educated Patients Decrease Fraud and Increase Quality of Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... The ... PCSK9 inhibitor prior authorization (PA) form for prescribers to improve patients’ access to ... the helpful tools published as part of the article entitled “PCSK9 Inhibitor ...
(Date:3/22/2017)... ... March 22, 2017 , ... Donor Network ... Nevada and LABS, Inc., announced the future opening of a CLIA certified dedicated ... serology testing used to determine the suitability of potential organ and tissue ...
(Date:3/22/2017)... Birmingham, Ala. (PRWEB) , ... March 22, 2017 ... ... consumer experience solution provider, today announced that its digital marketing solutions have enabled ... their marketing investment in 24 months. , Recognizing the value of a ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson ... new patients in need of skilled pediatric dentistry in Rock Hill, SC, ... pediatric patients routine treatments, including cavities, sealants and fluoride applications, in a comfortable and ...
(Date:3/22/2017)... ... ... Last year, 43 million gallons of surplus milk was reportedly dumped by ... dairy can be caused by several factors, one pharmaceutical company CEO suggests high rates ... lactose, a sugar found in milk and milk products. It is estimated ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Pharmaceutical Packaging ... over the next decade to reach approximately $129.81 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:3/22/2017)... -- Piramal Pharma Solutions (PPS), a leading ... event to introduce the new and expanded manufacturing capabilities ... . The inaugural event was attended by Governor ... and Piramal Pharma Solutions CEO, Vivek Sharma . ... ...
(Date:3/22/2017)... Mass. , March 22, 2017 Hologic, ... it has completed the acquisition of Cynosure, Inc., a ... per share in cash. "We are pleased ... to working with Michael Davin and the ... the large, rapidly growing medical aesthetics market," said ...
Breaking Medicine Technology: